Literature DB >> 1315863

Opioid and nicotinic analgesic and hyperalgesic loci in the rat brain stem.

S R Hamann1, W R Martin.   

Abstract

The effects of (-)-nicotine and ethylketazocine (EKC) on the latency of a low-intensity thermally evoked tail avoidance response were evaluated at different midline mesencephalic, pontomedullary and medullary sites of conscious intact rats. Guide cannulae were implanted surgically at six anterior-posterior stereotaxic locations (AP, -4.4 to +2.8) and drugs were microinjected (0.5 microliter) at different depths in each region. The analgesic effects of naltrexone and mecamylamine were evaluated at those sites exhibiting sensitivity to the hyperalgesic actions of (-)-nicotine and EKC. Additional experiments evaluated the validity and reproducibility of the low-intensity thermally evoked tail avoidance response and a low intensity hot plate response in detecting hyperalgesia. The chemostimulation studies suggest that there are opioid and nicotinic hyperalgesic processes distributed throughout the dorsal regions of the posterior mesencephalic and pontomedullary brain stem. The relative hyperalgesic potency of (-)-nicotine appears to exhibit a gradient from the dorsal posterior mesencephalic tegmentum to the midmedullary region, whereas only analgesia was produced more rostrally, in the central gray, or caudally within the posterior medulla. Within regions intermediate between the dorsal posterior, mesencephalic tegmentum and posterior medulla, (-)-nicotine produced biphasic dose-response and time action curves. The effects of EKC were similar to those of (-)-nicotine at most sites although (-)-nicotine was 55 times more potent than EKC when administered in the most active hyperalgesic regions.2+ may differ from region to region.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315863

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Endogenous opioids suppress activation of nociceptors by sub-nanomolar nicotine.

Authors:  F J Miao; N L Benowitz; J D Levine
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 2.  Nicotinic ACh receptors as therapeutic targets in CNS disorders.

Authors:  Kelly T Dineley; Anshul A Pandya; Jerrel L Yakel
Journal:  Trends Pharmacol Sci       Date:  2015-01-29       Impact factor: 14.819

3.  Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment.

Authors:  S M Crain; K F Shen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

4.  Short- and long-term enhancement of excitatory transmission in the spinal cord dorsal horn by nicotinic acetylcholine receptors.

Authors:  Jonathan R Genzen; Daniel S McGehee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-14       Impact factor: 11.205

Review 5.  Neuronal nicotinic receptors as analgesic targets: it's a winding road.

Authors:  Iboro C Umana; Claire A Daniele; Daniel S McGehee
Journal:  Biochem Pharmacol       Date:  2013-08-12       Impact factor: 5.858

6.  Mice lacking the β4 subunit of the nicotinic acetylcholine receptor show memory deficits, altered anxiety- and depression-like behavior, and diminished nicotine-induced analgesia.

Authors:  Svetlana Semenova; Candice Contet; Amanda J Roberts; Athina Markou
Journal:  Nicotine Tob Res       Date:  2012-05-09       Impact factor: 4.244

7.  Nicotine receptors mediating sensorimotor gating and its enhancement by systemic nicotine.

Authors:  Farena Pinnock; Daniel Bosch; Tyler Brown; Nadine Simons; John R Yeomans; Cleusa DeOliveira; Susanne Schmid
Journal:  Front Behav Neurosci       Date:  2015-02-11       Impact factor: 3.558

8.  Monocular diplopia-associated migraine-like headache induced by nicotine withdrawal.

Authors:  Xiaoping He; Alvina Munaf; Evgeny Idrisov; George Everett; Sami K Saikaly; Esther Kim; Khalid Abusaada; Vincent Hsu
Journal:  Clin Case Rep       Date:  2017-03-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.